| [1] Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent [J]. J Natl Cancer Inst, 1990, 82 (15): 1247–1259.
[2] Rowinsky EK, Donehower RC. Paclitaxel (taxol) [J]. N Engl J Med, 1995, 332 (15): 1004–1014.
[3] Crown J, O’Leary M. The taxanes: an update [J]. Lancet, 2000, 355 (9210): 1176–1178.
[4] Soepenberg O, Sparreboom A de Jonge MJ, et al. Real-time pharmacokinetics guiding clinical decisions; phase I study of a weekly schedule of liposome encapsulated paclitaxel in patients with solid tumours [J]. Eur J Cancer, 2004, 40 (5): 681–688.
[5] Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies [J]. J Clin Oncol, 2005, 23 (31): 7785–7793.
[6] Rodrigues DG, Maria DA, Fernandes DC, et al. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies [J]. Cancer Chemother Pharmacol, 2005, 55 (6): 565–576.
[7] Marcel Musteata F, Pawliszyn J. Determination of free concentration of paclitaxel in liposome formulation [J]. J Pharm Pharm Sci, 2006, 9 (2): 231–237.
[8] Fu RQ, He FC, Meng DS. Determination of paclitaxel in paclitaxel-loaded PLA nanoparticles by HPLC [J]. China Pharm, 2006, 15 (2): 32–33.
[9] Zhang JQ, Zhang ZR, Luo H. Determination of paclitaxel and the entrapment of its formulated preparations by RPHPLC [J]. West China J Pharm, 2001, 12 (2): 96–97.
[10] Straub JA, Chickering DE, Lovely JC, et al. Intravenous hydrophobic drug delivery: a porous particle formulation of paclitaxel (AI-850) [J]. Pharm Res, 2005, 22 (3): 347–55. |
>
>